[Stimulation of immunoreactivity against endogenous retroviruses and protection against leukemia in aged AKR mice after vaccination with antibodies to viral surface components. The role of antibodies to p15(E)] NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Stimulation of immunoreactivity against endogenous retroviruses and protection against leukemia in aged AKR mice after vaccination with antibodies to viral surface components. The role of antibodies to p15(E)]

Z Naturforsch [C]. 1984 Nov-Dec;39(11-12):1199-202. Unique Identifier : AIDSLINE MED/85170339
Schwarz H; Thiel HJ; Weinhold KJ; Bolognesi DP; Schafer W

Abstract: Antibody against viral gp71 is effective therapeutically for high leukemic AKR mice if injected immediately after birth. No corresponding effect could be observed after inoculation later in life when the endogenous virus burden is already high. However, if antibody treatment was supplemented by the injection of p15(E) antibody, a therapeutic effect was observed even in older mice first treated at an age of 21/2 months. Those mice produced antibodies against viral surface proteins and appeared to be able to survive longer than control mice. Thus p15(E) antibody might be able to overcome retroviral associated immuno-deficiency. This therapy may have implications for the treatment of the apparently retroviral induced acquired immunodeficiency syndrome (AIDS) of man.
Keywords: Aging Animal Antibodies, Viral/*THERAPEUTIC USE English Abstract IgG/ISOLATION & PURIF Leukemia, Experimental/*PREVENTION & CONTROL Mice Mice, Inbred AKR Retroviridae/*IMMUNOLOGY Viral Envelope Proteins/IMMUNOLOGY JOURNAL ARTICLE

KWDaginganimalantibodies,viral/KWDtherapeuticuseenglishabstractigg/isolation&purifleukemia,experimental/KWDprevention&controlmicemice,inbredakrretroviridae/KWDimmunologyviralenvelopeproteins/immunologyjournalarticle
850730
M8570166

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .